# Anaphylm™ (dibutepinephrine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dibutepinephrine

> The PDUFA target action date for Anaphylm™ (dibutepinephrine), sponsored by Aquestive Therapeutics, Inc. (AQST), is March 16, 2027, for type I allergic reactions. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the Anaphylm™ (dibutepinephrine) PDUFA date?

The PDUFA target action date for Anaphylm™ (dibutepinephrine), sponsored by Aquestive Therapeutics, Inc. (AQST), is March 16, 2027, for type I allergic reactions. Status: scheduled. Press release filed with the SEC (EX-99): "Anaphylm Regulatory Milestones 18 Q1 2027Q4 2026Q3 2026Q2 2026Q1 2026 NDA Resubmitted Targeted Ex-U.S. filing in Canada PDUFA Goal Date March 16, 2027" Last confirmed November 5, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/dibutepinephrine)

Source: Press release filed with the SEC (EX-99), accession 0001398733-26-000077, https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/dibutepinephrine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Anaphylm™ (dibutepinephrine) |
| Codes |  |
| Sponsor | Aquestive Therapeutics, Inc. (AQST) https://sec-api.dev/companies/aqst/catalysts |
| Indications | [type i allergic reactions](https://sec-api.dev/indications/type-i-allergic-reactions), [type 1 allergic reactions](https://sec-api.dev/indications/type-1-allergic-reactions) |
| Modality |  |
| FDA designations | fast track |

## Timeline

### Jun 2024: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-03-05, last confirmed 2026-11-03.
- SEC Form 10-Q (accession 0001398733-26-000074): "In June 2024, we reported positive topline PK data from the Company's temperature / pH study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm
- SEC Form 10-Q (accession 0001398733-26-000074): "In July 2024, we reported positive topline data from the self-administration PK study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm
- SEC Form 10-Q (accession 0001398733-26-000042): "In June 2024, we reported positive topline PK data from the Company's temperature / pH study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000042/aqst-20260630.htm
- SEC Form 10-Q (accession 0001398733-26-000042): "In July 2024, we reported positive topline data from the self-administration PK study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000042/aqst-20260630.htm
- SEC Form 10-Q (accession 0001398733-26-000030): "In June 2024, we reported positive topline PK data from the Company's temperature / pH study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000030/aqst-20260331.htm
- SEC Form 10-Q (accession 0001398733-26-000030): "In July 2024, we reported positive topline data from the self-administration PK study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000030/aqst-20260331.htm
- SEC Form 10-K (accession 0001398733-26-000018): "In June 2024, we reported positive topline PK data from the Company's temperature / pH study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm
- SEC Form 10-K (accession 0001398733-26-000018): "In July 2024, we reported positive topline data from the self-administration PK study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm
- SEC Form 10-Q (accession 0001398733-25-000028): "In June 2024, we reported positive topline PK data from the Company's temperature / pH study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000028/aqst-20250930.htm
- SEC Form 10-Q (accession 0001398733-25-000028): "In July 2024, we reported positive topline data from the self-administration PK study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000028/aqst-20250930.htm
- SEC Form 10-Q (accession 0001398733-25-000013): "In June 2024, we reported positive topline PK data from the Company's temperature / pH study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000013/aqst-20250630.htm
- SEC Form 10-Q (accession 0001398733-25-000013): "In July 2024, we reported positive topline data from the self-administration PK study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000013/aqst-20250630.htm

### Mar 2025: NDA/BLA submission

- Status: scheduled. Date confidence: month.
- First seen 2024-12-02, last confirmed 2025-03-10.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001229): "On track to submit Anaphylm™ (epinephrine) Sublingual Film NDA in Q1 2025" https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/aqstbusinessupdate2025-f.htm
- SEC Form 8-K (accession 0001628280-24-049497): "On December 2, 2024, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing receipt of positive feedback from the U.S. food and Drug Administration prior to its New Drug Application (NDA) submission for Anaphylm™ (epinephrine) Sublingual Film and reaffirmed NDA submission guidance in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1398733/000162828024049497/aqst-20241202.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-011465): "NDA submission underway and will be completed in March 2025 Anaphylm has the potential to be transformational 1." https://www.sec.gov/Archives/edgar/data/1398733/000162828025011465/corporatepresentationmar.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001229): "Aquestive is on track to submit the NDA for Anaphylm in the first quarter of 2025, with the goal of addressing critical unmet needs in severe allergy management." https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/aqstbusinessupdate2025-f.htm

### June 16, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: Type 1 allergic reactions.
- First seen 2025-06-16, last confirmed 2025-06-16.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-031455): "FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 - Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for Anaphylm™ in the treatment of Type 1 allergic reactions, including anaphylaxis, and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." https://www.sec.gov/Archives/edgar/data/1398733/000162828025031455/prndaacceptancedraft6-13.htm

### August 14, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-08-14, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-031008): "WARREN, N.J., August 14, 2025 - Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP ("RTW"), subject to United States Food and Drug Administration (FDA) approval of Anaphylm™ (epinephrine) Sublingual Film and other conditions." https://www.sec.gov/Archives/edgar/data/1398733/000114036125031008/ef20053941_ex99-1.htm

### January 31, 2026: PDUFA date

- Status: completed, complete response letter. Date confidence: exact. Indication: Type 1 allergic reactions.
- First seen 2025-06-16, last confirmed 2026-01-09.
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000003): "Anaphylm™ (dibutepinephrine) Sublingual Film The Company is in contact with the U.S. Food and Drug Administration (FDA) to gather further information about the deficiencies presently identified by the FDA in the New Drug Application (NDA) for Anaphylm, with the goal of addressing those deficiencies prior to the scheduled PDUFA action date of January 31, 2026, once disclosed to the Company." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aquestivepressrelease-fi.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-25-000022): "The Prescription Drug User Fee Act (PDUFA) target action date for Anaphylm is scheduled for January 31, 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000022/iprelease10-6x25.htm
- SEC Form 8-K (accession 0001398733-25-000016): "The Prescription Drug User Fee Act target action date for Anaphylm remains January 31, 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000016/aqst-20250904.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-25-000016): "The Prescription Drug User Fee Act (PDUFA) target action date for Anaphylm remains January 31, 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000016/adcompressrelease-9x3x25.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-25-000012): "•FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026" https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/q22025-ex991earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-031455): "FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 - Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for Anaphylm™ in the treatment of Type 1 allergic reactions, including anaphylaxis, and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." https://www.sec.gov/Archives/edgar/data/1398733/000162828025031455/prndaacceptancedraft6-13.htm
- SEC Form 10-Q (accession 0001398733-25-000028): "The PDUFA target action date for Anaphylm remains January 31, 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000028/aqst-20250930.htm
- SEC Form 10-Q (accession 0001398733-25-000028): "Anaphylm clinical trial expenses decreased $1,792, partially offset by increases in Anaphylm product research expenses of $151 due to the continued advancement of the Anaphylm program towards the PDUFA date of January 31, 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000028/aqst-20250930.htm
- SEC Form 10-Q (accession 0001398733-25-000028): "Anaphylm clinical trial expenses decreased $3,532 over the comparable period in 2024, partially offset by increases in Anaphylm product research expenses of $840 due to the continued advancement of the Anaphylm program towards the PDUFA date of January 31, 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000028/aqst-20250930.htm
- SEC Form 10-Q (accession 0001398733-25-000028): "The FDA has assigned a PDUFA target action date of January 31, 2026 for Anaphylm, and we are planning to initiate a product launch in Q1 2026, if approved by the FDA." https://www.sec.gov/Archives/edgar/data/1398733/000139873325000028/aqst-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-25-000020): "18 Anaphylm Key Milestones Pediatric Study Completed Q1 2025 NDA Submission Completed NDA Accepted by the FDA Potential ex-US Approval Filings Q2 2025 Q3 2025 Q4 2025 Q1 2026 PDUFA action date is scheduled for January 31, 2026" https://www.sec.gov/Archives/edgar/data/1398733/000139873325000020/corporatepresentationoct.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-031374): "An affiliate of RTW (the "Purchaser") has agreed to enter into a $75M revenue interest purchase and sale agreement (the "RIPSA") with Aquestive with substantially the following terms: Funding is contingent upon both FDA approval of Anaphylm (with a January 31, 2026 scheduled PDUFA date) and refinancing of Aquestive's existing 13.5% Senior Secured Notes; Royalties will be payable on Anaphylm annual net sales at the rate of 7.5% initially and scaling down to 1.0%, based on achievement of certain net sales thresholds; The royalty rate could increase to" https://www.sec.gov/Archives/edgar/data/1398733/000114036125031374/ef20053945_ex99-1.htm

### January 31, 2026: NDA/BLA acceptance

- Status: scheduled. Date confidence: exact.
- First seen 2025-08-11, last confirmed 2025-08-11.
- Press release filed with the SEC (EX-99) (accession 0001398733-25-000012): "•FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026" https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/q22025-ex991earningsrelease.htm

### February 2, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: Type I allergic reactions.
- First seen 2026-02-02, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000073): "Such risks and uncertainties include, but are not limited to, the possibility that the FDA may disagree with the Company's interpretation of study results, findings or conclusions, determine that the Anaphylm NDA resubmission does not adequately address the deficiencies identified in the January 30, 2026 Complete Response Letter, request additional information, analyses, human factors studies, clinical studies or inspections, consider issues raised in citizen petitions or similar submissions, or otherwise delay or decline approval" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000044): "The FDA issued a Complete Response Letter (CRL) on January 30, 2026, which requested that the Company complete a human factors study addressing packaging and administration, and a confirmatory pharmacokinetic (PK) study of Anaphylm." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/ndapressrelease-9x14x202.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000016): "On January 30, 2026, Aquestive received a Complete Response Letter (CRL) from the FDA for the New Drug Application (NDA) for Anaphylm in patients weighing 30 kilograms or more." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/aqst-q425xex991earningsrel.htm
- SEC Form 8-K (accession 0001398733-26-000005): "On February 2, 2026, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026, for the New Drug Application (NDA) seeking approval of Anaphylm™ (dibutepinephrine) Sublingual Film for the treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more (approximately 66 pounds)." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000005/aqst-20260130.htm
- SEC Form 10-K (accession 0001398733-26-000018): "•our ability to address the FDA's comments on and identified deficiencies in our NDA, including the concerns raised by the FDA in the Complete Response Letter dated January 30, 2026 issued to the Company for approval of Anaphylm;" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm
- SEC Form 10-K (accession 0001398733-26-000018): "On January 30, 2026, the Company received a CRL from the FDA for the NDA seeking approval of Anaphylm (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 33kg or more (approximately 66 pounds) that focused on administration and labeling guidance." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000007): "risks associated with our ability to address the FDA's comments on and identified deficiencies in our NDA, including the concerns raised by the FDA in the Complete Response Letter dated January 30 2026 issued to the Company for approval of Anaphylm and whether the FDA may request further information from us (including additional clinical studies), disagree with our findings or otherwise undertake a lengthy review of our resubmission, and challenges regarding the following commercial launch of Anaphylm, if approved by the FDA" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000007/corporatepresentationfeb.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000035): "Aquestive modified its packaging, labeling, and instructions for use for Anaphylm (dibutepinephrine) sublingual film in response to a Complete Response Letter received from the United States Food and Drug Administration (FDA) in January 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/hfandclinicalstudystudys.htm

### Q2 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2026-03-04, last confirmed 2026-03-04.
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000016): "Completed dosing in Phase 1 study and expect data readout in Q2 2026 Strengthened balance sheet provides needed cash to complete Anaphylm approval and progress Anaphylm ex-US" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/q42025supplementalearnin.htm

### Q3 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-03-04, last confirmed 2026-08-11.
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000041): "•Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/q22026-ex991earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000041): "The Company reaffirms its guidance to resubmit the Anaphylm New Drug Application (NDA) in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/q22026-ex991earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000035): "Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/humanfactorspkstudyresul.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000035): "Aquestive plans to include the HF and clinical PK study data as part of its Anaphylm NDA resubmission, which the Company is on track to complete in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/humanfactorspkstudyresul.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000035): "These forward-looking statements include, but are not limited to, statements regarding the results of the Company's Human Factors (HF) validation study and pharmacokinetic (PK) study for Anaphylm™ (dibutepinephrine) sublingual film; the significance, interpretation and sufficiency of those study results; the Company's belief that such results support its efforts to address concerns raised by the U.S. Food and Drug Administration (FDA) in the Complete Response Letter dated January 30, 2026; the planned resubmission of the Anaphylm New Drug Application (NDA) during the third quarter of 2026; the timing and outcome of FDA review of the NDA resubmission; potential international regulatory" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/humanfactorspkstudyresul.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000029): "•Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/q12026-ex991earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000029): ""We successfully completed our Type A meeting with the FDA, aligning on the study designs needed to support resubmission of the Anaphylm NDA, which we continue to target for the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/q12026-ex991earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000029): "The Company reaffirms its guidance to resubmit the Anaphylm New Drug Application (NDA) in the third quarter of 2026, subject to completion of the required studies and expected FDA response timelines." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/q12026-ex991earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000022): "Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000022/typeameetingpressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000022): "Based on the outcome of the Type A meeting, Aquestive reaffirms its guidance to resubmit the Anaphylm NDA in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000022/typeameetingpressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000016): "•Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 days" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/aqst-q425xex991earningsrel.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000016): "Our Non-GAAP adjusted EBITDA loss guidance for 2026 includes costs associated with the resubmission of the NDA for Anaphylm, continued pre-commercial infrastructure spending for Anaphylm, clinical trial for AQST-108, and regulatory applications for Anaphylm in Canada and the EU." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/aqst-q425xex991earningsrel.htm

### Aug 2026: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2026-09-17, last confirmed 2026-09-17.
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000044): "Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/ndapressrelease-9x14x202.htm

### September 17, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: Type I allergic reactions.
- First seen 2026-09-17, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000073): "On September 16, 2026, the Company resubmitted its New Drug Application (NDA) for Anaphylm to the U.S. Food and Drug Administration (FDA)." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000058): "Aquestive submitted the resubmission to the Anaphylm NDA on September 16, 2026, following the August 2026 announcement of positive topline results from human factors and pharmacokinetic (PK) studies conducted to address the items raised in the FDA's January 30, 2026, Complete Response Letter." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000058/a2026-10x19aquestivepduf.htm
- SEC Form 8-K (accession 0001398733-26-000044): "On September 17, 2026, the Company issued a press release announcing it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/aqst-20260914.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000044): "FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., September 17, 2026 -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/ndapressrelease-9x14x202.htm
- SEC Form 10-Q (accession 0001398733-26-000074): "On September 16, 2026, the Company resubmitted the Anaphylm New Drug Application to the FDA, and on September 17, 2026, the Company announced the resubmission." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm

### September 30, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000077): "Cash Position Supports Anaphylm Review and Launch Preparation 9 $90.3 million in cash and cash equivalents as of September 30, 2026 Potential access to $75 million under a strategic funding agreement with RTW Investments, subject to applicable conditions including FDA approval of Anaphylm An additional $20 million potentially available under the Oaktree Capital Management debt facility, subject to applicable conditions including FDA approval of Anaphylm; no assurance either facility will become available" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm

### March 16, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: Type I allergic reactions.
- First seen 2026-10-15, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000077): "Anaphylm Regulatory Milestones 18 Q1 2027Q4 2026Q3 2026Q2 2026Q1 2026 NDA Resubmitted Targeted Ex-U.S. filing in Canada PDUFA Goal Date March 16, 2027" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000077): "Anaphylm advances toward a March 16, 2027, PDUFA goal date following FDA acceptance of the NDA resubmission." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000073): "•Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000073): ""With a PDUFA goal date of March 16, 2027, we believe we have a clear path to making Anaphylm available to patients and caregivers, if approved," said Daniel Barber, President and Chief Executive Officer of Aquestive." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm
- SEC Form 8-K (accession 0001398733-26-000058): "On October 15, 2026, Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, as complete and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027." https://www.sec.gov/Archives/edgar/data/1398733/000139873326000058/aqst-20261015.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000058): "Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000058/a2026-10x19aquestivepduf.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000077): "the FDA's review of the accepted Class 2 resubmission of the NDA and the Prescription Drug User Fee Act ("PDUFA") goal date of March 16, 2027" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000073): "PDUFA goal date is March 16, 2027" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/thirdquarter2026earnings.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000058): "Prescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000058/a2026-10x19aquestivepduf.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000073): "These forward-looking statements include, but are not limited to, statements regarding the FDA's review of the accepted Class 2 resubmission of the NDA for Anaphylm™ (dibutepinephrine) sublingual film and potential approval by the March 16, 2027 PDUFA goal date" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000073): "the FDA's review of the Class 2 resubmission of the Anaphylm NDA and potential approval by the March 16, 2027 PDUFA goal date" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/thirdquarter2026earnings.htm
- SEC Form 10-Q (accession 0001398733-26-000074): "the FDA's review of the Class 2 resubmission of the Anaphylm NDA and potential approval by the March 16, 2027 PDUFA goal date" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm

### March 16, 2027: NDA/BLA submission

- Status: scheduled. Date confidence: exact.
- First seen 2026-11-03, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001398733-26-000073): "the FDA's review of the Class 2 resubmission of the Anaphylm NDA and potential approval by the March 16, 2027 PDUFA goal date" https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/thirdquarter2026earnings.htm

Calendar months: [January 2026](https://sec-api.dev/fda-calendar/2026-01), [March 2027](https://sec-api.dev/fda-calendar/2027-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dibutepinephrine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Anaphylm™ (dibutepinephrine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dibutepinephrine

```bibtex
@misc{secapidev_pdufa_dibutepinephrine_20261116,
  title        = {Anaphylm™ (dibutepinephrine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dibutepinephrine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dibutepinephrine_20261116","title":"Anaphylm™ (dibutepinephrine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dibutepinephrine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
